08/24 Taiwan BIO Weekly
2026-08-24 |
| Taiwan BIO Weekly |
| TLC BioSciences' Degenerative Arthritis Drug Completes Japanese Clinical Trial 20 August, 2026 TLC BioSciences (TW: 7924) announced that its long-acting osteoarthritis drug candidate TLC599 has completed the last patient last visit (LPLV) in a Japanese pharmacokinetic (PK) trial, paving the way for a multinational Phase III trial in the US and Japan, and strengthening the company's position in licensing negotiations with leading Japanese pharmaceutical companies. More... (in Chinese) |
| Lotus Pharmaceutical's Generic Drug Receives Japanese Marketing Approval 20 August, 2026 Lotus Pharmaceutical (TW: 1795) announced that its generic pomalidomide capsule, the generic version of POMALYST, has received marketing approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA), in 1mg, 2mg, 3mg, and 4mg strengths. The approval marks Lotus's second product to gain Japanese authorization following its generic lenalidomide in 2023. The company will partner with Fuji Pharma to launch the product, making it one of the first generic pomalidomide products available in the Japanese market. More... (in Chinese) |
| Genovior Capital Increase to Accelerate Drug Development and Commercialization 19 August, 2026 Genovior (TW: 6917) announced that it has received regulatory approval for its 2026 cash capital increase, planning to issue 6,000 lots of new shares at NT$32 per share to raise NT$192 million to support its drug development and commercialization efforts. Its lead candidate APC201 is a 505(b)(2) topical foam being developed for localized knee osteoarthritis pain, featuring a proprietary dual-action lipid formulation that eliminates the need for irritating DMSO, enables a 4% drug concentration--twice that of competing products--and is designed to enhance pain relief while reducing skin irritation. More... (in Chinese) |
| Top-tier journals cover NTUH's bacteria screening 19 August, 2026 A two-decade research effort by National Taiwan University Hospital (NTUH) to develop a two-in-one screening program for Helicobacter pylori, bacteria that increase the risk of colorectal and stomach cancer, has been featured in leading international medical journals and could potentially be adopted by some eastern European and South American countries. More... |
| ScinoPharm Focuses on Three Core Businesses, Expands Weight-Loss Drug Strategy 18 August, 2026 ScinoPharm Taiwan (TW: 1789) reported a loss in the first half of 2026 and plans to optimize production capacity allocation in the second half, while focusing on its three core businesses: proprietary APIs, CDMO services, and finished-dose formulations. The company is also expanding its weight-loss drug portfolio, having submitted a US FDA application for an injectable weight-management drug and filed for approval of a GLP-1 injectable diabetes treatment in Taiwan, with regulatory approval expected soon. More... (in Chinese) |
| Medigen's EV71 Vaccine Shows Long-Lasting Protection, Targets School-Age Market Expansion 18 August, 2026 Medigen Vaccine Biologics (TW: 6547) announced on August 17th that its self-developed EV71 vaccine has achieved a major clinical milestone after the company was invited to deliver an oral presentation at the 12th Asian Congress of Pediatric Infectious Diseases (ACPID 2026) in Bandung, Indonesia. As one of the most prominent pediatric infectious disease conferences in the Asia-Pacific region, the invitation reflects strong recognition from international experts of the scientific quality and clinical advances of Medigen's research. More... (in Chinese) |
| Pancreatic cancer study shares findings 18 August, 2026 A study by researchers at the National Health Research Institutes (NHRI) found that having low levels of serum carbohydrate antigen 19-9 (CA19-9), a pancreatic tumor biomarker, in people with pancreatic cancer does not necessarily indicate a better prognosis. More... |
| PharmaEssentia Expands Indications for Ropeg 17 August, 2026 PharmaEssentia (TW: 6446) is further expanding the therapeutic applications of its drug Ropeg (P1101). The company announced on August 16th that it has submitted an application to Taiwan's Food and Drug Administration (TFDA) to expand Ropeg's indication for essential thrombocythemia (ET) to all adult patients, regardless of treatment line. It has also applied to revise the dosing regimen for polycythemia vera (PV), introducing a high-dose rapid dose-escalation protocol. More... (in Chinese) |
| ITRI develops tech therapy for anxiety 17 August, 2026 The Industrial Technology Research Institute (ITRI) has developed Taiwan's first digital therapeutic technology for generalized anxiety disorder (GAD), which combines noninvasive micro-electrical stimulation of the vagus nerve through the ear with physiological data analysis. More... |
| Trust Bio-sonics' Next-Gen Contrast Agent Enters US Phase III; Taiwan Trial Readout Nears 14 August, 2026 On August 13th Trust Bio-sonics announced that its next-generation ultrasound microbubble contrast agent, TBS-002, has enrolled the first patient in its US Phase III trial (NH002). The trial will enroll 150 participants and is expected to complete enrollment and unblinding in 2027. Meanwhile, the Taiwan Phase III trial of TBS-002 has completed enrollment and is expected to be unblinded soon. The company said the clinical trial, approved by the US FDA, is designed to evaluate the safety and efficacy of TBS-002 in enhancing image quality during clinical echocardiography. More... (in Chinese) |
| ========================================= |
| Please note that Taiwan BIO is not responsible for the accuracy of third-party news stories covered in this newsletter. |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |